CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

D. Max Smith, Kristin W. Weitzel, Amanda R. Elsey, Taimour Langaee, Yan Gong, Dyson T. Wake, Benjamin Q. Duong, Melanie Hagen, Chris Harle, Elvira Mercado, Ying Nagoshi, Kimberly Newsom, Ashleigh Wright, Eric I. Rosenberg, Petr Starostik, Michael J. Clare-Salzler, Siegfried O. Schmidt, Roger B. Fillingim, Julie A. Johnson, Larisa H. Cavallari

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. Methods: Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS® measures. Results: On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24% of CYP2D6-guided versus 0% of usual care participants reported ≥30% (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540). Conclusion: These data support the potential benefits of CYP2D6-guided pain management.

Original languageEnglish (US)
JournalGenetics in Medicine
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Pragmatic Clinical Trials
Cytochrome P-450 CYP2D6
Opioid Analgesics
Pain
Tramadol
Codeine
Therapeutics
Pain Management
Chronic Pain
Analgesia
Linear Models
Genotype

Keywords

  • chronic pain
  • CYP2D6
  • opioids
  • pharmacogenetics
  • precision medicine

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Smith, D. M., Weitzel, K. W., Elsey, A. R., Langaee, T., Gong, Y., Wake, D. T., ... Cavallari, L. H. (Accepted/In press). CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genetics in Medicine. https://doi.org/10.1038/s41436-018-0431-8

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers : a pragmatic clinical trial. / Smith, D. Max; Weitzel, Kristin W.; Elsey, Amanda R.; Langaee, Taimour; Gong, Yan; Wake, Dyson T.; Duong, Benjamin Q.; Hagen, Melanie; Harle, Chris; Mercado, Elvira; Nagoshi, Ying; Newsom, Kimberly; Wright, Ashleigh; Rosenberg, Eric I.; Starostik, Petr; Clare-Salzler, Michael J.; Schmidt, Siegfried O.; Fillingim, Roger B.; Johnson, Julie A.; Cavallari, Larisa H.

In: Genetics in Medicine, 01.01.2019.

Research output: Contribution to journalArticle

Smith, DM, Weitzel, KW, Elsey, AR, Langaee, T, Gong, Y, Wake, DT, Duong, BQ, Hagen, M, Harle, C, Mercado, E, Nagoshi, Y, Newsom, K, Wright, A, Rosenberg, EI, Starostik, P, Clare-Salzler, MJ, Schmidt, SO, Fillingim, RB, Johnson, JA & Cavallari, LH 2019, 'CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial', Genetics in Medicine. https://doi.org/10.1038/s41436-018-0431-8
Smith, D. Max ; Weitzel, Kristin W. ; Elsey, Amanda R. ; Langaee, Taimour ; Gong, Yan ; Wake, Dyson T. ; Duong, Benjamin Q. ; Hagen, Melanie ; Harle, Chris ; Mercado, Elvira ; Nagoshi, Ying ; Newsom, Kimberly ; Wright, Ashleigh ; Rosenberg, Eric I. ; Starostik, Petr ; Clare-Salzler, Michael J. ; Schmidt, Siegfried O. ; Fillingim, Roger B. ; Johnson, Julie A. ; Cavallari, Larisa H. / CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers : a pragmatic clinical trial. In: Genetics in Medicine. 2019.
@article{4666ce2243654e25b34f652e69e2902d,
title = "CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial",
abstract = "Purpose: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. Methods: Participants with chronic pain (94{\%} on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS{\circledR} measures. Results: On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24{\%} of CYP2D6-guided versus 0{\%} of usual care participants reported ≥30{\%} (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540). Conclusion: These data support the potential benefits of CYP2D6-guided pain management.",
keywords = "chronic pain, CYP2D6, opioids, pharmacogenetics, precision medicine",
author = "Smith, {D. Max} and Weitzel, {Kristin W.} and Elsey, {Amanda R.} and Taimour Langaee and Yan Gong and Wake, {Dyson T.} and Duong, {Benjamin Q.} and Melanie Hagen and Chris Harle and Elvira Mercado and Ying Nagoshi and Kimberly Newsom and Ashleigh Wright and Rosenberg, {Eric I.} and Petr Starostik and Clare-Salzler, {Michael J.} and Schmidt, {Siegfried O.} and Fillingim, {Roger B.} and Johnson, {Julie A.} and Cavallari, {Larisa H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41436-018-0431-8",
language = "English (US)",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers

T2 - a pragmatic clinical trial

AU - Smith, D. Max

AU - Weitzel, Kristin W.

AU - Elsey, Amanda R.

AU - Langaee, Taimour

AU - Gong, Yan

AU - Wake, Dyson T.

AU - Duong, Benjamin Q.

AU - Hagen, Melanie

AU - Harle, Chris

AU - Mercado, Elvira

AU - Nagoshi, Ying

AU - Newsom, Kimberly

AU - Wright, Ashleigh

AU - Rosenberg, Eric I.

AU - Starostik, Petr

AU - Clare-Salzler, Michael J.

AU - Schmidt, Siegfried O.

AU - Fillingim, Roger B.

AU - Johnson, Julie A.

AU - Cavallari, Larisa H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. Methods: Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS® measures. Results: On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24% of CYP2D6-guided versus 0% of usual care participants reported ≥30% (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540). Conclusion: These data support the potential benefits of CYP2D6-guided pain management.

AB - Purpose: CYP2D6 bioactivates codeine and tramadol, with intermediate and poor metabolizers (IMs and PMs) expected to have impaired analgesia. This pragmatic proof-of-concept trial tested the effects of CYP2D6-guided opioid prescribing on pain control. Methods: Participants with chronic pain (94% on an opioid) from seven clinics were enrolled into CYP2D6-guided (n = 235) or usual care (n = 135) arms using a cluster design. CYP2D6 phenotypes were assigned based on genotype and CYP2D6 inhibitor use, with recommendations for opioid prescribing made in the CYP2D6-guided arm. Pain was assessed at baseline and 3 months using PROMIS® measures. Results: On stepwise multiple linear regression, the primary outcome of composite pain intensity (composite of current pain and worst and average pain in the past week) among IM/PMs initially prescribed tramadol/codeine (n = 45) had greater improvement in the CYP2D6-guided versus usual care arm (-1.01 ± 1.59 vs. -0.40 ± 1.20; adj P = 0.016); 24% of CYP2D6-guided versus 0% of usual care participants reported ≥30% (clinically meaningful) reduction in the composite outcome. In contrast, among normal metabolizers prescribed tramadol or codeine at baseline, there was no difference in the change in composite pain intensity at 3 months between CYP2D6-guided (-0.61 ± 1.39) and usual care (-0.54 ± 1.69) groups (adj P = 0.540). Conclusion: These data support the potential benefits of CYP2D6-guided pain management.

KW - chronic pain

KW - CYP2D6

KW - opioids

KW - pharmacogenetics

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85060544208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060544208&partnerID=8YFLogxK

U2 - 10.1038/s41436-018-0431-8

DO - 10.1038/s41436-018-0431-8

M3 - Article

AN - SCOPUS:85060544208

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

ER -